Oppenheimer Q2 Review on Cadence Pharma (CADX): Supply Shortage Not Expected From Recall
Tweet Send to a FriendGet Alerts CADX Hot Sheet
Price: $6.70 -4.15%
Rating Summary:
6 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 14
Rating Summary:
6 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 14
Trade CADX Now!
Oppenheimer maintains a 'Perform' on Cadence Pharma (NASDAQ: CADX).
Analyst, Christopher Holterhoff, said, "On 8/2, CADX reported 2Q12 adj. EPS of ($0.19), above our ($0.25) estimate, as lower than expected revenues were more than offset by lower than expected operating costs. We highlight that OFIRMEV revenues grew 38% to ~$11.1M (vs. our $12.8M estimate and consensus of $10.9M) during the quarter. While OFIRMEV sales have exhibited some positive trends, we estimate these to be reflected in the current share price. We lower our 3Q12 OFIRMEV sales estimates (from $19.6M to $14.2M) on updated management guidance. Importantly, we believe the current 2013 consensus number for OFIRMEV ($97.2M), which is above our $77.2M estimate, could prove to be too aggressive."
FY12 EPS estimate raised from (0.73) to (0.57) and FY13 from (0.63) to (0.33)
For an analyst ratings summary and ratings history on Cadence Pharma click here. For more ratings news on Cadence Pharma click here.
Shares of Cadence Pharma closed at $4.07 yesterday, with a 52 week range of $2.56-$8.65.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Christopher Holterhoff, said, "On 8/2, CADX reported 2Q12 adj. EPS of ($0.19), above our ($0.25) estimate, as lower than expected revenues were more than offset by lower than expected operating costs. We highlight that OFIRMEV revenues grew 38% to ~$11.1M (vs. our $12.8M estimate and consensus of $10.9M) during the quarter. While OFIRMEV sales have exhibited some positive trends, we estimate these to be reflected in the current share price. We lower our 3Q12 OFIRMEV sales estimates (from $19.6M to $14.2M) on updated management guidance. Importantly, we believe the current 2013 consensus number for OFIRMEV ($97.2M), which is above our $77.2M estimate, could prove to be too aggressive."
FY12 EPS estimate raised from (0.73) to (0.57) and FY13 from (0.63) to (0.33)
For an analyst ratings summary and ratings history on Cadence Pharma click here. For more ratings news on Cadence Pharma click here.
Shares of Cadence Pharma closed at $4.07 yesterday, with a 52 week range of $2.56-$8.65.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Benchmark Boosts PT on R.R. Donnelley (RRD)
- Deutsche Bank Raises PT on NetApp (NTAP) to $48
- The ExOne Company (XONE) Metal Opportunity to Keep Stock Going - FBR
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
